Alkermes schizophrenia treatment meets main goals in late-stage study

Alkermes Plc said on Thursday its treatment for schizophrenia met the main goals in a late-stage study and demonstrated a favorable weight profile, compared with antipsychotic agent olanzapine.

from Reuters: Health News https://ift.tt/2Rla8mv